NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), featuring a year-to-date gain of 52.77% and upside potential of 987.00%, secures a spot on our list of hot biotech stocks under $5 to buy.

A clinical-stage biopharmaceutical company focused on bringing suicide-prevention drugs to market, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), just closed a capital raise that provides it with a fresh runway to push its pipeline forward.

On June 4, 2026, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) closed an underwritten public offering of its common stock at $3.50 per share, generating gross proceeds of approximately $22.3 million before underwriting discounts, commissions, and other offering expenses. That figure reflects the exercise of the underwriters’ option to purchase additional shares. The company said it plans to use the net proceeds for working capital and general corporate purposes.

The closing followed shortly after the pricing announcement.

On June 3, 2026, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) priced 5,714,286 shares at $3.50 each, with gross proceeds initially projected at approximately $20.0 million, or up to $23.0 million if the underwriters exercised their 30-day option to purchase up to an additional 857,142 shares in full. BTIG, LLC acted as lead bookrunning manager, with Lucid Capital Markets, LLC serving as joint bookrunning manager.

The offering process began on June 2, 2026, when NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its intention to launch the deal, subject to market conditions.

“In an era where an American dies from suicide every 11 minutes, we feel honored to be part of the potential solution,” said Chairman and CEO Jonathan Javitt, MD, MPH.

Founded in 2015 and headquartered in Wilmington, NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies targeting central nervous system disorders, including severe suicidal depression, post-traumatic stress disorder, and bipolar depression.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.